Aytu Biopharma, Inc (AYTU): Cost of Revenue
$20.75M
Year ended 2026-06-30
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $20.75M | +1.0% | 2026-09-22, From 2025-07-01 |
| 2025-06-30 | $20.55M | +27.4% | 2026-09-22, From 2024-07-01 |
| 2024-06-30 | $16.13M | n/c | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $40.77M | -8.2% | 2024-09-26, From 2022-07-01 |
| 2022-06-30 | $44.39M | +21.8% | 2023-10-12, From 2021-07-01 |
| 2021-06-30 | $36.43M | +339.9% | 2022-09-27, From 2020-07-01 |
| 2020-06-30 | $8.28M | n/c | 2021-09-28, From 2019-07-01 |
| 2019-06-30 | $2.20M | +7.4% | 2020-10-06, From 2018-07-01 |
| 2018-06-30 | $2.05M | +44.7% | 2019-09-26, From 2017-07-01 |
| 2017-06-30 | $1.42M | +48.1% | 2018-09-06, From 2016-07-01 |
| 2016-06-30 | $957.1K | +986.2% | 2017-08-31, From 2015-07-01 |
| 2015-06-30 | $88.1K | n/a | 2016-09-01, From 2014-07-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $20.75M | +1.0% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $0 | -100.0% |
| Journey Medical Corp (DERM) | 2025-12-31 | $20.92M | +0.2% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $6.34M | +52.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $20.92M | +0.2% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $6.57M | +16.9% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $274.0K | -55.5% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.56M | -31.5% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $18.55M | +3.8% |
Compare AYTU, NKTR, DERM, AGIO side by side · Screen every company in Pharmaceutical Preparations ↗